According to GuruFocus Insider Data, the recent CFO sells were: Allison Transmission Holdings Inc. (ALSN, Financial) and Vertex Pharmaceuticals Inc. (VRTX, Financial).
Allison Transmission Holdings Inc.
President and CFO David S. Graziosi sold 46,200 shares for $45.03 per share on Jan. 09. Since then, the stock price has decreased by 1.51%. Allison Transmission Holdings Inc. has a market cap of $6.29 billion and its shares were traded around $44.35. The company has a P/E ratio of 19.62 and P/S ratio of 3.21. The trailing 12-month dividend yield of Allison Transmission Holdings Inc. stocks is 1.37%, while the forward dividend yield is 1.35%. Over the past five years, Allison Transmission Holdings Inc. had an annual average earnings growth of 1.60%.
Allison Transmission Holdings announced its third-quarter results with revenue of $595 million and gross profit of $302 million, while the net income was $111 million. The 2016 total revenue was $1.84 billion, a 7% decrease from 2015. The 2016 gross profit was $864.2 million, a 7% decrease from the year prior. The 2016 net income was $214.9 million.
Director James A. Star sold 505,005 shares for $44.65 per share on Jan. 12. Since then, the stock price has decreased by 0.67%. Senior Vice President Operations and Purchasing Michael Dick sold 6,565 shares for $45 per share on Jan. 9. Since then, the stock price has decreased by 1.44%. Vice President, Counsel and Secretary Eric C. Scroggins sold 4,330 shares for $44 per share on Jan. 3. Since then, the stock price has increased by 0.8%.
Vertex Pharmaceuticals Inc.
CFO Thomas Graney sold 777 shares for $149.95 per share on Jan. 2. Since then, the stock price has increased by 4.83%. Vertex Pharmaceuticals Inc. has a market cap of $39.75 billion and its shares were traded around $157.19. The company has a P/E ratio of 201.52 and P/S ratio of 17.07.
Vertex announced its third-quarter results with revenue of $578.17 million and gross profit of $505.29 million, while the net loss was $102.95 million. The 2016 total revenue was $1.7 billion, a 65% increase from 2015. The 2016 gross profit was $1.49 billion, a 64% increase from the year prior. The 2016 net loss was $112.05 million.
CEO and President Jeffrey M. Leiden sold 99,563 shares for $156.99 per share on Jan. 16. Since then, the stock price has increased by 0.13%. EVP, Global Research and CSO David Altshuler sold 56,250 shares for $156.99 per share on Jan. 16. Since then, the stock price has increased by 0.13%. EVP, COO Ian F. Smith sold 2,125 shares for $157.29 per share on Jan. 16. Since then, the stock price has decreased by 0.06%.
Disclosure: None.
